LBA9_PRCetuximab versus cisplatin in patients with HPV-positive, low risk oropharyngeal cancer, receiving radical radiotherapy. (23rd October 2018) - Mehanna, H; Kong, A; Hartley, A; Mistry, P; Dalby, M; Fulton-Lieuw, T; Robinson, M; Gray, A; Foran, B; Sen, M; O'Toole, L; Dyker, K; et al.